Continuous glucose monitor

Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation

Retrieved on: 
Friday, October 28, 2022
Prenatal nutrition, Diabetes, Continuous glucose monitor, Safety, Life, FreeStyle, Paganini Competition, Technology, Research, MitraClip, Nobel Prize, Film, Pharmaceutical industry, Medical device

The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.

Key Points: 
  • The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.
  • "The Prix Galien Golden Jubilee Awards honor the global 'best of the best' innovations that have improved the human condition over the last 50 years," said Bruno Cohen, Chairman of the Galien Foundation.
  • Over the years, Abbott has received 11 Prix Galien Awards for its innovations in pharmaceuticals and medical technology, including for Humira, MitraClipand FreeStyle Libre.
  • FreeStyle Libre 2 and FreeStyle Libre 3 systems:Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.

Automatic Blood Glucose Monitoring Pioneer Intuity Medical Appoints Industry Veteran George Zamanakos President and CEO

Retrieved on: 
Thursday, October 27, 2022
LifeScan, McKinsey & Company, Growth, Johnson & Johnson, Diabetes, Automatic, Leadership, FDA, Continuous glucose monitor, Quality of life, CEO, Health, Physics, Anderson, POGO, Pharmaceutical industry, Dexcom, California Institute of Technology

FREMONT, Calif., Oct. 27, 2022 /PRNewswire/ -- Intuity Medical, Inc., a medical technology company with the mission of making life with diabetes easier, today announced the appointment of George Zamanakos as President and CEO.

Key Points: 
  • FREMONT, Calif., Oct. 27, 2022 /PRNewswire/ -- Intuity Medical, Inc., a medical technology company with the mission of making life with diabetes easier, today announced the appointment of George Zamanakos as President and CEO.
  • Zamanakos succeeds Emory Anderson, who led the company over the past 14 years in the development and last year's launch of its POGO Automatic Blood Glucose Monitoring System.
  • "On behalf of the board, we are pleased to welcome George to lead Intuity Medical as we venture into the next phase of the company's development.
  • Intuity Medical's POGO Automatic Blood Glucose Monitoring System is the only FDA-cleared automatic blood glucose monitoring system that lances and collects blood in just one step with 10-test cartridge technology, ending the need to individually load lancets and test strips (as required by other blood glucose meters).

Continuous Glucose Monitoring (CGM) Market to Grow by 13% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Health, Diabetes, Adoption, Disease, Diabetes, Risk, Government, Hospital, Therapy, TIR, Glucose oxidase, Population, Platinum, CAGR, Patient, Virus, Science, Technology, Partnership, Glucose meter, CGM, Continuous glucose monitor, Association, Korean Association of Retired Persons, Death, COVID-19, USD, Pharmaceutical industry, Medical imaging, Medical device, Growth, Spectrum

The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Continuous Glucose Monitoring (CGM) Market is expected to register a CAGR greater than 13% over the forecast period, 2022-2027.
  • Governments around the world developed programs to educate diabetes patients and health care providers about the usage of continuous glucose monitoring devices.
  • Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients.

Continuous Glucose Monitoring (CGM) Market Report 2022: Featuring Abbott, Roche, Tandem Diabetes Care, Dexcom Inc & Senseonics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022
Diabetes, Health, Medical Devices, Diabetes, Adoption, Insight, COVID-19, Roche, Prevalence, Blood, Industry, Tandem Diabetes Care, Continuous glucose monitor, Technology, Glucose meter, CGM, US, Abbott Laboratories, Dexcom, Medical device, Growth

According to the publisher, Continuous Glucose Monitoring Market is estimated to reach US$ 8.48 Billion by 2027.

Key Points: 
  • According to the publisher, Continuous Glucose Monitoring Market is estimated to reach US$ 8.48 Billion by 2027.
  • One of the most recent technical evolutions in diabetes management is continuous glucose monitoring (CGM).
  • In brief, a CGM system is a form of glucose monitoring device that works by inserting a biosensor either transcutaneously or subcutaneously.
  • Unlike traditional glucose monitors, these devices allow for continuous glucose monitoring, which is critical for avoiding diabetic complications.

Global Digital Diabetes Management Market to Reach $21.9 Billion by 2030 at an 8% CAGR

Retrieved on: 
Wednesday, September 28, 2022
Digital, Blood, Ageing, Prevalence, Smartphone, Population, Obesity, Partnership, Diabetes, USD, Patient, Attention, Insulin, Artificial intelligence, Awareness, Disease management, Continuous glucose monitor, CAGR, Medical device, Sanofi

The global digital diabetes management market size is expected to reach USD 21.90 billion by 2030, according to this report.

Key Points: 
  • The global digital diabetes management market size is expected to reach USD 21.90 billion by 2030, according to this report.
  • The market is expected to expand at a CAGR of 8.0% from 2022 to 2030.
  • Digital diabetes management tools help patients analyze their glucose levels and pattern.
  • The market growth is further augmented by the increasing prevalence of obesity, the growing aging population, and increasing awareness regarding diabetes preventive care.

Global Diabetes Care Devices Market Analysis/Forecasts Report 2022: A $42 Billion Market by 2028 - Rapid Technological Advancements in Diabetes Care Devices - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022
Diabetes, Health, Fitness & Nutrition, Diabetes, Lubrication, Food and Drug Administration, Cannula, Incidence, COVID-19, Blood, FDA, Food, Prevalence, Growth, Hindustan Syringes & Medical Devices, Needle, Patient, Insulin, Medical device, Technology, Medtronic, CGM, Syringe, Medical tourism, Method, Research, Skin, HMD, Continuous glucose monitor, CAGR, Pharmaceutical industry, Beauty salon, Tourism, EU

However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth

Key Points: 
  • However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth
    Technological advancements in the healthcare industry are encouraging market players to focus on research and development of insulin delivery devices.
  • The continuous research in insulin pens supports the growth of the global diabetes care devices market during the forecast period.
  • The diabetes care devices allow diabetes patients to monitor and manage their diabetes in their homes.
  • The prevalence of type 1 diabetes patients is likely to fuel the demand for diabetes care devices.

Global Digital Diabetes Management Market Report 2022: Rise of Disease Management Smartphone Apps Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Diabetes, Health, Data Management, Technology, Artificial Intelligence, Digital, Blood, Ageing, Prevalence, Smartphone, Population, Obesity, Partnership, Diabetes, USD, Patient, Attention, Insulin, Artificial intelligence, Awareness, Disease management, Continuous glucose monitor, CAGR, Medical device, Sanofi

The "Digital Diabetes Management Market Size, Share & Trends Analysis Report by Product (Continuous Blood Glucose Monitoring System, Smart Insulin Pen), by Type, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digital Diabetes Management Market Size, Share & Trends Analysis Report by Product (Continuous Blood Glucose Monitoring System, Smart Insulin Pen), by Type, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global digital diabetes management market size is expected to reach USD 21.90 billion by 2030, according to this report.
  • The number of smartphone apps for disease management has seen a monumental rise over the past few years, giving the market a major boost.
  • The market growth is further augmented by the increasing prevalence of obesity, the growing aging population, and increasing awareness regarding diabetes preventive care.

2022 Continuous Glucose Monitoring Systems Market Report: A $4.43 Bn Market in 2021 - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 22, 2022
Diabetes, Health, Medical Devices, Continuity, Culture, USD, Industry, Continuous glucose monitor, CAGR, Video game

The "Continuous Glucose Monitoring Systems Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring Systems Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Continuous Glucose Monitoring Systems Market is projected to reach USD 8,794.97 million by 2027 from USD 4,432.35 million in 2021, at a CAGR 12.09% during the forecast period.
  • The report on continuous glucose monitoring systems identifies key attributes about the customer to define the potential market and identify different needs across the industry.
  • The Americas Continuous Glucose Monitoring Systems Market size was estimated at USD 1,335.31 million in 2021, is expected to reach USD 1,480.39 million in 2022, and is projected to grow at a CAGR of 11.78% to reach USD 2,605.00 million by 2027.

Global Insulin Pumps and Continuous Glucose Monitors Market Insights to 2030 - Players Include Medtronic, DexCom, Abbott Laboratories and Ypsomed Holdings - ResearchAndMarkets.com

Retrieved on: 
Friday, July 8, 2022
Medical Supplies, Health, Medical Devices, Diabetes, Health Technology, Managed Care, Biotechnology, People, Review, Zealand Pharma, Insulin, COVID-19, SWOT analysis, Others, Syringe, Country, Dexcom, Abbott Laboratories, Investment, Segment, Market access, Type 1 diabetes, Reading, Blood, Epidemiology, Medtronic, Region, Continuous glucose monitor, Internet, ASP, Medical device, Retail, Forecast

The model discusses in detail the impact of COVID-19 on Insulin Pumps and Continuous Glucose Monitors Devices market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Insulin Pumps and Continuous Glucose Monitors Devices market for the year 2020 and beyond.
  • People with insulin-dependent diabetes require intensive insulin therapy to manage their blood glucose levels within a healthy range.
  • Insulin can be delivered by syringes and vials, insulin pumps, and insulin pens.
  • Insulin Pumps include Traditional Insulin Pumps & Accessories and Patch Pumps.

Rimidi Expands Team by 86%, Grows Revenue by 100% in First Half of 2022

Retrieved on: 
Wednesday, July 6, 2022
Efficiency, Path, ACO, LinkedIn, CEO, Research, Conditional sentence, Vive, Accountable care organization, CMS, Abbott, Growth, Ecosystem, Goal, SMART, Compliance, Continuous glucose monitor, Partnership, 21st Century Cures Act, EHR, Technology, Workflow, Organization, Doctor of Philosophy, Business partner, National Association, Solution, HIMSS, Twitter, News, MD, FHIR, Medical device, Sales, Medicine, Facebook

ATLANTA, July 6, 2022 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today that the company has expanded its employee base by 86% and seen a 100% growth in revenue, accompanied by an enlargement of its Atlanta headquarters. The overarching company growth and momentum further underscores Rimidi's commitment and ability to create innovative solutions for its hospital, health system, and provider customers that result in better workflows, experiences, and outcomes.

Key Points: 
  • Rimidi continues to be a leader in enterprise software for chronic disease management and clinical workflow optimization, including remote patient monitoring and clinical decision support.
  • Recent additions to the team will further support the company in developing a sustainable product roadmap and a secure, scalable software platform.
  • "Our employee growth across quality, compliance, product and client success is pivotal to achieving this goal."
  • Heading into the second half of 2022, Rimidi has additional product and technology developments planned, including new disease modules, device integrations, and EHR partners.